☰

Christopher Asquith, Ph.D. - Publications

Affiliations: 
2016-2018 SGC-UNC University of North Carolina, Chapel Hill, Chapel Hill, NC 
 2022- School of Pharmacy University of Eastern Finland 
Website:
https://uefconnect.uef.fi/en/person/christopher.asquith/
Tree Info Similar researchers PubMed Report error

24 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Bieberich AA, Asquith CRM. Utilization of Supervised Machine Learning to Understand Kinase Inhibitor Toxophore Profiles. International Journal of Molecular Sciences. 24. PMID 36982163 DOI: 10.3390/ijms24065088  0.637
2022 Murray NH, Asquith CRM, Fang Z, East MP, Ptak N, Smith RW, Vasta JD, Zimprich CA, Corona CR, Robers MB, Johnson GL, Bingman CA, Pagliarini DJ. Small-molecule inhibition of the archetypal UbiB protein COQ8. Nature Chemical Biology. PMID 36302899 DOI: 10.1038/s41589-022-01168-3  0.502
2022 Bieberich AA, Laitinen T, Maffuid K, Fatig RO, Torrice CD, Morris DC, Crona DJ, Asquith CRM. Optimization of the 4-anilinoquin(az)oline scaffold as epidermal growth factor receptor (EGFR) inhibitors for chordoma utilizing a toxicology profiling assay platform. Scientific Reports. 12: 12820. PMID 35896603 DOI: 10.1038/s41598-022-15552-5  0.51
2022 Karim M, Saul S, Ghita L, Sahoo MK, Ye C, Bhalla N, Lo CW, Jin J, Park JG, Martinez-Gualda B, East MP, Johnson GL, Pinsky BA, Martinez-Sobrido L, Asquith CRM, et al. Numb-associated kinases are required for SARS-CoV-2 infection and are cellular targets for antiviral strategies. Antiviral Research. 105367. PMID 35738348 DOI: 10.1016/j.antiviral.2022.105367  0.42
2022 Asquith CRM, Temme L, East MP, Laitinen T, Pickett J, Kwarcinski FE, Sinha P, Wells CI, Johnson GL, Zutshi R, Drewry DH. Identification of 4-anilino-quin(az)oline as a cell active Protein Kinase Novel 3 (PKN3) inhibitor chemotype. Chemmedchem. PMID 35403825 DOI: 10.1002/cmdc.202200161  0.566
2021 Kalogirou AS, East MP, Laitinen T, Torrice CD, Maffuid KA, Drewry DH, Koutentis PA, Johnson GL, Crona DJ, Asquith CRM. Synthesis and Evaluation of Novel 1,2,6-Thiadiazinone Kinase Inhibitors as Potent Inhibitors of Solid Tumors. Molecules (Basel, Switzerland). 26. PMID 34641454 DOI: 10.3390/molecules26195911  0.493
2021 Eduful BJ, O'Byrne SN, Temme L, Asquith CRM, Liang Y, Picado A, Pilotte JR, Hossain MA, Wells CI, Zuercher WJ, Catta-Preta CMC, Zonzini Ramos P, Santiago AS, Couñago RM, Langendorf CG, et al. Hinge Binder Scaffold Hopping Identifies Potent Calcium/Calmodulin-Dependent Protein Kinase Kinase 2 (CAMKK2) Inhibitor Chemotypes. Journal of Medicinal Chemistry. PMID 34264658 DOI: 10.1021/acs.jmedchem.0c02274  0.693
2021 Wells CI, Al-Ali H, Andrews DM, Asquith CRM, Axtman AD, Dikic I, Ebner D, Ettmayer P, Fischer C, Frederiksen M, Futrell RE, Gray NS, Hatch SB, Knapp S, Lücking U, et al. The Kinase Chemogenomic Set (KCGS): An Open Science Resource for Kinase Vulnerability Identification. International Journal of Molecular Sciences. 22. PMID 33429995 DOI: 10.3390/ijms22020566  0.686
2020 Saul S, Pu SY, Zuercher WJ, Einav S, Asquith CRM. Potent antiviral activity of novel multi-substituted 4-anilinoquin(az)olines. Bioorganic & Medicinal Chemistry Letters. 30: 127284. PMID 32631507 DOI: 10.1016/j.bmcl.2020.127284  0.443
2020 Asquith CRM, Tizzard GJ, Bennett JM, Wells CI, Elkins JM, Willson TM, Poso A, Laitinen T. Targeting the water network in cyclin G associated kinase (GAK) with 4-anilino-quin(az)oline inhibitors. Chemmedchem. PMID 32358915 DOI: 10.1002/cmdc.202000150  0.662
2020 Asquith CRM, Laitinen T, Wells CI, Tizzard GJ, Zuercher WJ. New Insights into 4-Anilinoquinazolines as Inhibitors of Cardiac Troponin I-Interacting Kinase (TNNi3K). Molecules (Basel, Switzerland). 25. PMID 32272798 DOI: 10.3390/molecules25071697  0.529
2019 Asquith CRM, Bennett JM, Su L, Laitinen T, Elkins JM, Pickett JE, Wells CI, Li Z, Willson TM, Zuercher WJ. Towards the Development of an In vivo Chemical Probe for Cyclin G Associated Kinase (GAK). Molecules (Basel, Switzerland). 24. PMID 31698822 DOI: 10.3390/molecules24224016  0.639
2019 Asquith CRM, Laitinen T, Bennett JM, Wells CI, Elkins JM, Zuercher WJ, Tizzard G, Poso A. Design and analysis of the 4-anilino-quin(az)oline kinase inhibition profiles of GAK/SLK/STK10 using quantitative structure activity relationships. Chemmedchem. PMID 31675459 DOI: 10.1002/cmdc.201900521  0.613
2019 Asquith CRM, Murray NH, Pagliarini DJ. ADCK3/COQ8A: the choice target of the UbiB protein kinase-like family. Nature Reviews. Drug Discovery. 18: 815. PMID 31673128 DOI: 10.1038/D41573-019-00158-W  0.394
2019 Carabajal MA, Asquith CRM, Laitinen T, Tizzard GJ, Yim L, Rial A, Chabalgoity JA, Zuercher WJ, García Véscovi E. Quinazoline-based anti-virulence compounds selectively target PhoP/PhoQ signal transduction system. Antimicrobial Agents and Chemotherapy. PMID 31611347 DOI: 10.1128/AAC.01744-19  0.381
2019 Asquith CRM, Maffuid KA, Laitinen T, Torrice CD, Tizzard GJ, Crona DJ, Zuercher WJ. Targeting an EGFR Water Network with 4-Anilinoquin(az)oline Inhibitors for Chordoma. Chemmedchem. 14: 1693-1700. PMID 31424613 DOI: 10.1002/cmdc.201900428  0.474
2019 Asquith CRM, Fleck N, Torrice CD, Crona DJ, Grundner C, Zuercher WJ. Anti-tubercular activity of novel 4-anilinoquinolines and 4-anilinoquinazolines. Bioorganic & Medicinal Chemistry Letters. PMID 31378571 DOI: 10.1016/J.Bmcl.2019.07.012  0.339
2019 Asquith CRM, East MP, Zuercher WJ. RIOK2: straddling the kinase/ATPase line. Nature Reviews. Drug Discovery. 18: 574. PMID 31367048 DOI: 10.1038/d41573-019-00107-7  0.412
2019 Asquith CRM, Treiber DK, Zuercher WJ. Utilizing comprehensive and mini-kinome panels to optimize the selectivity of quinoline inhibitors for cyclin G associated kinase (GAK). Bioorganic & Medicinal Chemistry Letters. 29: 1727-1731. PMID 31129055 DOI: 10.1016/j.bmcl.2019.05.025  0.598
2019 Asquith CRM, Naegeli K, East M, Laitinen T, Havener T, Wells C, Johnson G, Drewry D, Zuercher W, Morris D. Design of a cyclin G associated kinase (GAK)/epidermal growth factor receptor (EGFR) inhibitor set to interrogate the relationship of EGFR and GAK in chordoma. Journal of Medicinal Chemistry. PMID 30973735 DOI: 10.1021/Acs.Jmedchem.9B00350  0.496
2019 Asquith CRM, Berger BT, Wan J, Bennett JM, Capuzzi SJ, Crona DJ, Drewry D, East MP, Elkins JM, Fedorov O, Godoi PH, Hunter DM, Knapp S, Müller S, Torrice CD, et al. SGC-GAK-1: a chemical probe for cyclin G associated kinase (GAK). Journal of Medicinal Chemistry. PMID 30768268 DOI: 10.1021/acs.jmedchem.8b01213  0.696
2018 Strang BL, Asquith CRM, Moshrif HF, Ho CM, Zuercher WJ, Al-Ali H. Identification of lead anti-human cytomegalovirus compounds targeting MAP4K4 via machine learning analysis of kinase inhibitor screening data. Plos One. 13: e0201321. PMID 30048526 DOI: 10.1371/Journal.Pone.0201321  0.459
2018 Asquith CRM, Godoi PH, Couñago RM, Laitinen T, Scott JW, Langendorf CG, Oakhill JS, Drewry DH, Zuercher WJ, Koutentis PA, Willson TM, Kalogirou AS. 1,2,6-Thiadiazinones as Novel Narrow Spectrum Calcium/Calmodulin-Dependent Protein Kinase Kinase 2 (CaMKK2) Inhibitors. Molecules (Basel, Switzerland). 23. PMID 29783765 DOI: 10.3390/Molecules23051221  0.696
2017 Asquith CRM, Laitinen T, Bennett JM, Godoi PH, East MP, Tizzard GJ, Graves LM, Johnson GL, Dornsife RE, Wells CI, Elkins JM, Willson TM, Zuercher W. Identification and Optimization of 4-Anilinoquinolines as Inhibitors of Cyclin G Associated Kinase. Chemmedchem. PMID 29072804 DOI: 10.1002/Cmdc.201700663  0.694
Show low-probability matches.